Drugs

, Volume 74, Issue 5, pp 563–578 | Cite as

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

Adis Drug Evaluation

Abstract

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) [Sativex®] is an oromucosal spray formulation that contains principally THC and CBD at an approximately 1:1 fixed ratio, derived from cloned Cannabis sativa L. plants. The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2), and thus, may modulate the effects of excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) neurotransmitters. THC/CBD is approved in a number of countries, including Germany and the UK, as an add-on treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. In the largest multinational clinical trial that evaluated the approved THC/CBD regimen in this population, 12 weeks’ double-blind treatment with THC/CBD significantly reduced spasticity severity (primary endpoint) compared with placebo in patients who achieved a clinically significant improvement in spasticity after 4 weeks’ single-blind THC/CBD treatment, as assessed by a patient-rated numerical rating scale. A significantly greater proportion of THC/CBD than placebo recipients achieved a ≥30 % reduction (a clinically relevant reduction) in spasticity severity. The efficacy of THC/CBD has been also shown in at least one everyday clinical practice study (MOVE 2). THC/CBD was generally well tolerated in clinical trials. Dizziness and fatigue were reported most frequently during the first 4 weeks of treatment and resolved within a few days even with continued treatment. Thus, add-on THC/CBD is a useful symptomatic treatment option for its approved indication.

References

  1. 1.
    Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1–2):2–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):Iii (ix–x, 1–111).PubMedGoogle Scholar
  3. 3.
    Multiple Sclerosis Trust. Multiple sclerosis information for health and social care professionals. http://www.mstrust.org.uk/downloads/ms-info-health-professionals.pdf (2011). Accessed 8 Jul 2013.
  4. 4.
    Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Slof J, Gras A. Sativex in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439–41.PubMedCrossRefGoogle Scholar
  6. 6.
    National Collaborating Centre for Chronic Conditions (UK). Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. NICE clinical guidelines, no 8. London: Royal College of Physicians (UK); 2004.Google Scholar
  7. 7.
    Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;4:CD001332.PubMedGoogle Scholar
  8. 8.
    Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24(6):511–6.Google Scholar
  9. 9.
    Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59(3):291–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Baker D, Pryce G, Jackson SJ, et al. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult Scler Relat Disord. 2012;1(2):64–75.CrossRefGoogle Scholar
  11. 11.
    Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol. 2007;150(4):519–25.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Guy GW, Stott CG. The development of Sativex®—a natural cannabis-based medicine. In: Mechoulam R, editor. Cannabinoids as therapeutics. Basel: Birkhäuser Basel; 2005. p. 231–63.CrossRefGoogle Scholar
  13. 13.
    Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011;25(3):187–201.PubMedCrossRefGoogle Scholar
  14. 14.
    GW Pharma Ltd. Sativex oromucosal spray: summary of product characteristics. http://www.medicines.org.uk/emc/medicine/23262/SPC/Sativex+Oromucosal+Spray/ (2012). Accessed 29 Jan 2014.
  15. 15.
    Hilliard A, Stott C, Wright S, et al. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. ISRN Neurol. 2012. doi:10.5402/2012/802649.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Bayer Healthcare. Sativex® oromucosal spray: product specification. http://www.sativex.co.uk/data/file/Sativex%20Product%20SpecDocument.pdf (2010). Accessed 29 Jan 2014.
  17. 17.
    Medicines and Healthcare products Regulatory Agency. Public assessment report: Sativex oromucosal spray (decentralized procedure reference number UKH/2462/001/DC). http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf (2010). Accessed 28 May 2013.
  18. 18.
    Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17(1):21–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther. 2011;89(3):400–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Schoedel KA, Chen N, Hilliard A, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011;26(3):224–36.PubMedGoogle Scholar
  21. 21.
    Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41–7.PubMedGoogle Scholar
  22. 22.
    Wright S, Vachova MM, Novakova I. The effect of long-term treatment with a prescription cannabis-based THC: CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to multiple sclerosis (abstract no. P1206). Mult Scler. 2013;19(suppl 11):572.Google Scholar
  23. 23.
    Guy GW, Robson PJ. Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther. 2003;3(4):79–120.CrossRefGoogle Scholar
  24. 24.
    Stott C, White L, Wright S, et al. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. SpringerPlus. 2013;2(1):236.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Stott CG, White L, Wright S, et al. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013;69(4):825–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013;69(5):1135–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16(5):276–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639–45.PubMedCrossRefGoogle Scholar
  33. 33.
    Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260(1):285–95.PubMedCrossRefGoogle Scholar
  34. 34.
    Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler. 2012;18(2):219–28.PubMedCrossRefGoogle Scholar
  35. 35.
    Farrell RA, Flisher L, Broome K, et al. Sativex: an alternative to intrathecal baclofen in patients with severe multiple sclerosis-related spasticity? (abstract no. P650). Mult Scler. 2013;19(suppl 11):284.Google Scholar
  36. 36.
    Arnal C, Carrion F. Structured diagnosis and management with THC:CBD oromucosal spray of patients with resistant multiple sclerosis spasticity (abstract no. P1110). Mult Scler. 2013;19(suppl 11):522.Google Scholar
  37. 37.
    Flachenecker P, Zettl U, Henze T. THC:CBD oromucosal spray (nabiximols) in the long term treatment of multiple sclerosis spasticity. The MOVE 2 long-term study (abstract no. P1121). Mult Scler. 2013;19(suppl 11):527.Google Scholar
  38. 38.
    Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice—results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71(5–6):173–81.Google Scholar
  39. 39.
    Koehler J, Feneberg W, Meier M, et al. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci. 2014;. doi:10.3109/00207454.2013.877460.PubMedGoogle Scholar
  40. 40.
    Garcia-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother. 2013;13(3 suppl. 1):9–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Wade DT, Collin C, Stott C, et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707–14.PubMedCrossRefGoogle Scholar
  42. 42.
    Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther. 2008;30(5):974–85.PubMedCrossRefGoogle Scholar
  43. 43.
    Eltayb A, Etges T, Wright S. An observational post-approval registry study of patients prescribed Sativex®. Results from clinical practice (abstract no. P1041). Mult Scler. 2013;19(suppl 11):480.Google Scholar
  44. 44.
    Freidel M, Tiel-Wilck K, Schreiber H, et al. Resistant multiple sclerosis spasticity (MSS) treatment with THC:CBD spray and effects on driving ability (abstract no. P1111). Mult Scler. 2013;19(suppl 11):522.Google Scholar
  45. 45.
    Royal College of Physicians and Multiple Sclerosis Trust. The national audit of services for people with multiple sclerosis 2011. http://www.rcplondon.ac.uk/sites/default/files/ms_audit_national_report_2011_0.pdf (2011). Accessed 29 Jan 2014.
  46. 46.
    Lu L, Pearce H, Roome C, et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex) for spasticity in multiple sclerosis. Pharmacoeconomics. 2012;30(12):1157–71.PubMedCrossRefGoogle Scholar
  47. 47.
    National Institute for Health and Care Excellence. Measuring effectiveness and cost effectiveness: the QALY. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp (2010). Accessed 7 Aug 2013.
  48. 48.
    GW Pharmaceuticals. GW pharmaceuticals files new regulatory application to expand Sativex® approval to France. http://www.gwpharm.com/GW%20Pharmaceuticals%20Files%20New%20Regulatory%20Application%20to%20Expand%20Sativex%20Approval%20to%20France.aspx (2013). Accessed 2 Aug 2013.
  49. 49.
    Multiple Sclerosis Trust. Sativex (nabiximols)—factsheet. http://www.mstrust.org.uk/information/publications/factsheets/sativex.jsp (2011). Accessed 2 Aug 2013.
  50. 50.
    Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12 suppl):55–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Yahiya Y. Syed
    • 1
  • Kate McKeage
    • 1
  • Lesley J. Scott
    • 1
  1. 1.AdisAucklandNew Zealand

Personalised recommendations